Name | Number of supported studies | Average coverage | |
---|---|---|---|
macrophage | 22 studies | 37% ± 17% | |
microglial cell | 16 studies | 43% ± 18% | |
alveolar macrophage | 8 studies | 68% ± 15% | |
monocyte | 8 studies | 42% ± 17% | |
myeloid cell | 7 studies | 38% ± 11% | |
classical monocyte | 6 studies | 38% ± 20% | |
conventional dendritic cell | 6 studies | 34% ± 6% | |
dendritic cell | 4 studies | 30% ± 8% | |
leukocyte | 3 studies | 43% ± 4% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
lung | 6 studies | 20% ± 4% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
lung | 100% | 5404.56 | 577 / 578 | 82% | 28.13 | 942 / 1155 |
brain | 81% | 785.19 | 2127 / 2642 | 92% | 42.35 | 650 / 705 |
kidney | 87% | 569.22 | 77 / 89 | 83% | 23.58 | 746 / 901 |
breast | 41% | 142.97 | 190 / 459 | 91% | 25.79 | 1018 / 1118 |
pancreas | 39% | 141.50 | 127 / 328 | 88% | 36.50 | 157 / 178 |
thymus | 38% | 109.00 | 247 / 653 | 59% | 9.55 | 358 / 605 |
stomach | 31% | 62.91 | 110 / 359 | 47% | 6.79 | 133 / 286 |
bladder | 24% | 47.14 | 5 / 21 | 51% | 21.87 | 256 / 504 |
ovary | 8% | 13.78 | 14 / 180 | 63% | 10.16 | 272 / 430 |
prostate | 38% | 89.70 | 92 / 245 | 28% | 2.84 | 141 / 502 |
uterus | 9% | 23.71 | 15 / 170 | 48% | 19.54 | 221 / 459 |
peripheral blood | 50% | 775.91 | 464 / 929 | 0% | 0 | 0 / 0 |
skin | 15% | 49.94 | 271 / 1809 | 32% | 5.04 | 152 / 472 |
blood vessel | 44% | 357.27 | 586 / 1335 | 0% | 0 | 0 / 0 |
esophagus | 5% | 7.94 | 68 / 1445 | 39% | 8.78 | 71 / 183 |
intestine | 6% | 12.45 | 56 / 966 | 34% | 6.94 | 180 / 527 |
adrenal gland | 26% | 64.18 | 68 / 258 | 13% | 2.38 | 31 / 230 |
adipose | 39% | 225.61 | 464 / 1204 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 31% | 4.92 | 14 / 45 |
liver | 7% | 20.67 | 16 / 226 | 12% | 2.77 | 48 / 406 |
spleen | 18% | 60.18 | 43 / 241 | 0% | 0 | 0 / 0 |
heart | 16% | 53.28 | 140 / 861 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 3% | 0.20 | 1 / 29 |
eye | 0% | 0 | 0 / 0 | 1% | 0.10 | 1 / 80 |
muscle | 0% | 0.99 | 4 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0002376 | Biological process | immune system process |
GO_0006954 | Biological process | inflammatory response |
GO_0042157 | Biological process | lipoprotein metabolic process |
GO_0016192 | Biological process | vesicle-mediated transport |
GO_0006508 | Biological process | proteolysis |
GO_0008015 | Biological process | blood circulation |
GO_0007159 | Biological process | leukocyte cell-cell adhesion |
GO_0043235 | Cellular component | receptor complex |
GO_0005576 | Cellular component | extracellular region |
GO_0035579 | Cellular component | specific granule membrane |
GO_0005886 | Cellular component | plasma membrane |
GO_0045121 | Cellular component | membrane raft |
GO_0016020 | Cellular component | membrane |
GO_0005654 | Cellular component | nucleoplasm |
GO_0070821 | Cellular component | tertiary granule membrane |
GO_0043231 | Cellular component | intracellular membrane-bounded organelle |
GO_0030246 | Molecular function | carbohydrate binding |
GO_0042802 | Molecular function | identical protein binding |
GO_0005041 | Molecular function | low-density lipoprotein particle receptor activity |
GO_0005515 | Molecular function | protein binding |
Gene name | OLR1 |
Protein name | Oxidized low-density lipoprotein receptor 1 (Ox-LDL receptor 1) (C-type lectin domain family 8 member A) (Lectin-like oxidized LDL receptor 1) (LOX-1) (Lectin-like oxLDL receptor 1) (hLOX-1) (Lectin-type oxidized LDL receptor 1) [Cleaved into: Oxidized low-density lipoprotein receptor 1, soluble form] Oxidized low density lipoprotein receptor 1 (cDNA, FLJ79252, weakly similar to Oxidized low-density lipoprotein receptor 1) Oxidized low density lipoprotein receptor 1 Oxidized low-density lipoprotein receptor 1 (Lectin-like oxidized LDL receptor 1) (Lectin-type oxidized LDL receptor 1) |
Synonyms | CLEC8A LOX1 |
Description | FUNCTION: Receptor that mediates the recognition, internalization and degradation of oxidatively modified low density lipoprotein (oxLDL) by vascular endothelial cells. OxLDL is a marker of atherosclerosis that induces vascular endothelial cell activation and dysfunction, resulting in pro-inflammatory responses, pro-oxidative conditions and apoptosis. Its association with oxLDL induces the activation of NF-kappa-B through an increased production of intracellular reactive oxygen and a variety of pro-atherogenic cellular responses including a reduction of nitric oxide (NO) release, monocyte adhesion and apoptosis. In addition to binding oxLDL, it acts as a receptor for the HSP70 protein involved in antigen cross-presentation to naive T-cells in dendritic cells, thereby participating in cell-mediated antigen cross-presentation. Also involved in inflammatory process, by acting as a leukocyte-adhesion molecule at the vascular interface in endotoxin-induced inflammation. Also acts as a receptor for advanced glycation end (AGE) products, activated platelets, monocytes, apoptotic cells and both Gram-negative and Gram-positive bacteria. .; FUNCTION: (Microbial infection) May serve as a receptor for adhesin A variant 3 (nadA) of N.meningitidis. . |
Accessions | ENST00000543414.1 P78380 ENST00000339968 B7ZAN8 ENST00000544577.5 ENST00000432556.6 [P78380-2] F5H001 F5H7N8 ENST00000538745.5 F5H3G7 J3QTI8 F5GZH1 ENST00000309539.8 [P78380-1] ENST00000543993.5 F5H0N6 ENST00000538873.1 ENST00000545927.5 [P78380-3] ENST00000539518.5 |